Subscribe to the Dovetail weekly digest & magazine

 
 

Required fields

 
 

October 17, 2014

NCPIC WEBINAR: SYNTHETIC CANNABINOIDS

The National Cannabis Prevention and Intervention Centre (NCPIC) has announced a webinar on Monday 3rd of November 2014 on the topic of "Synthetic Cannabinoids" with Professor Steve Allsop, Director of the National Drug Research Institute (NDRI).  The presentation will provide an up to date overview of synthetic cannabinoids including prevalence, short and long term risks, consumer's views about synthetic cannabinoids and more.  If you are interested in attending you need to register in advance.

Register here for Professor Steve Allsop presenting on "Synthetic Cannabinoids"

Read More

 

June 20, 2014

THE ETHICS OF COGNITIVE ENHANCEMENT

An article has been published on The Conversation website titled "Put down the smart drugs: Cognitive enhancement ethically risky business".  The article, authored by Associate Professor Nicole Vincent  from Georgia State University, and Emma Jane from University of New South Wales, considers the growing body of research into the use and implications of the use of cognitive enhancing substances such as Modafinil, Ritilin and Donepezil, as well as emerging technologies such as Transcranial Direct Current Stimulation devices.  While research appears to indicate increases in the use of these products, there are potentially a number of serious health concerns, but there are also ethical implications that require interrogation.

Go to "Put down the smart drugs: Cognitive enhancement ethically risky business".

Read More

 

May 30, 2014

SAFER INJECTING INFORMATION FOR PEOPLE WHO USE NEW PSYCHOACTIVE SUBSTANCES

New Psychoactive Substances (sometimes referred to as Emerging Psychoactive Substances) have been appearing with increasing regularity over the past few years.  There is evidence that some of these substances are being injected, particularly the cathinone-type stimulants such as MDPV.  There are a number of potential injecting harms from these substances, yet very little accurate information is currently available.  To help remedy this, the Scottish Drugs Forum have published a guide for people who may be injecting New Psychoactive Substances, called "Safer Injecting Basics for New Psychoactive Substances."  The guide can be downloaded as a PDF and includes a general overview of some of the possible risks associated with these substances and strategies to reduce the harms.

Go to "Safer Injecting Basics for New Psychoactive Substances"

Read More

 

May 9, 2014

UPDATED INFORMATION ON NEW PSYCHOACTIVE SUBSTANCES

The Australian Drug Foundation have updated their information on new and emerging psychoactive substances.  They have published a general fact sheet on new and emerging drugs, designed to provide an overview of the issue for people who only need a basic description, but they've also got specific facts sheets for synthetic cannabinoids and the NBOMe-type substances.

Go to the Australian Drug Foundation's "New psychoactive substances" page for more information.

Read More

 

November 15, 2013

THE NEW ZEALAND APPROACH TO EMERGING PSYCHOACTIVE SUBSTANCES

Many countries around the world are grappling with the rise of new and emerging substances.  These substances present many challenges for policy makers, and currently a range of different policy responses are being trialled.  New Zealand has taken a unique approach, allowing manufacturers the opportunity to have their products tested to establish some level of safety.  Substances that are found through clinical trials to meet the safety criteria will be allowed to be supplied to people aged over 18.  Ross Bell, the Executive Director of the New Zealand Drug Foundation, recently have an interview where he described the history of emerging drugs in New Zealand and he explains the policy approach.

Go to "Ross Bell: Discussion on the New Zealand Psychoactive Substances Bill"

 

Read More

 

September 13, 2013

PUBLIC HEALTH AND LEGAL IMPLICATIONS OF EMERGING PSYCHOACTIVE DRUGS

The journal "Addiction" has dedicated its current online September edition to the issue of emerging psychoactive substances. Included is a report on acute toxicity from confirmed consumption of synthetic cannabinoids, an overview of the New Zealand approach to regulating these substances, health impacts of mephedrone and public health challenges posed by the rapid changes occurring in this area.  The journal is freely available without a subscription until the 30th of September.

Go to "Addiction" journal website.

Read More

 

August 30, 2013

NBOME: A VERY DIFFERENT KETTLE OF FISH

A recent edition of the Medical Journal of Australia has published an article by Dr David Caldicott, Stephen Bright and Monica Barratt titled "NBOMe - A very different kettle of fish".  The article describes the recent media interest in the substance 25I-NBOMe, believed responsible for the death of Sydney teenager Henry Kwan.  Numerous media reports stated that this substance was available online for $1.50 per tab, and that it was being sold as LSD.  The authors believe that this type of reporting is likely to result in increased use of the substance and may in fact lead some to on-sell NBOMe as LSD in order to make a significant profit. Observations of online marketplaces indicate that NBOMe tabs are available for purchase in Australia containing 1200 micrograms per tab, however an effective dose may be as small as 200 - 1000 micrograms.  There is significant risks of further harm from this substance, as emerging evidence indicates possible cardiovascular complications, hyperthermia, metabolic acidosis, organ failure and death.

Read "NBOMe: A very different kettle of fish"

Read More

 

August 9, 2013

NBOMe Health Risks

Evidence continues to come to light showing the health risks associated with the emerging psychoactive substance 25I-NBOMe. The drug (sometimes being sold as LSD) is suspected of being responsible for a number of deaths across Australia and throughout the world. The substance is active in the microgram dose range and has been appearing on blotter paper, causing some people to believe they are consuming LSD.  Recently, it is believed that one of the NBOMe series of chemicals has also appeared in tablets sold as Ecstasy, leading to the hospitalisation of several people in Adelaide. Anex has published some harm reduction information for people who may be using LSD, while further research is underway to better understand this emerging substance.

Read More

 

June 28, 2013

DEMYSTIFYING THE CHEMISTRY OF SYNTHETIC CANNABINOIDS

The European Monitoring Centre for Drugs and Drug Addiction have published a website with further information on the chemistry of synthetic cannabinoids.  The site contains an interactive graphic that demonstrates the chemical make up of various synthetic cannabinoids and cannabinoid mimetics.  The site is designed to make the chemistry of these new substances easier to understand for the lay person who doesn't have a background in chemistry.

 

Go to "Synthethic cannabinoids in Europe"

 

Read More

 

June 7, 2013

DOVETAIL WEBINAR AVAILABLE ONLINE SHORTLY

We recently held our first webinar on the topic of "Emerging Drugs", which was a resounding success.  We are currently editing up a video of the presentation which we will have available online in the next couple of weeks.  Because the content of the presentation is designed specifically for workers, we are going to keep the web link private.  If you would like to watch a video of the presentation, please send an email to info@dovetail.org.au and we can send you a link to view the presentation on YouTube.  Stay tuned for future webinars on a range of topics.

Read More